Twist Bioscience Opens New Twist Boston Location
SOUTH SAN FRANCISCO, Calif. – July 6, 2022 – Twist Bioscience Corporation (NASDAQ: TWST), a...
Tracey Mullen, SVP Operations Twist Bioscience
Mice are one of the most common repertoire sources for in vivo antibody discovery. The choice of mouse model, immunization method, and/or screening strategy can significantly impact the drug discovery and development timeline. In this webinar, the scientific leadership of Abveris will discuss the following topics:
1. Challenges in the discovery of therapeutic antibodies against cell surface receptors and transmembrane proteins such as GPCR and ion channels
2. Overview of key selected technologies to access development-ready therapeutic leads, including the use of humanized mice and humanization of murine antibodies
3. A case study of an antibody discovery campaign against a cell surface receptor target using both humanized mice and proprietary hyperimmune (DiversimAb) mice for a risk-mitigated workflow under a rapid timeline
Here are more on-demand webinars that our team has put together for you